The promising results of several multicenter studies during the last few years have improved the immunomodulatory treatment of multiple sclerosis (MS). The different compounds tested were shown to reduce the number of relapses and to modulate the course of disease to various extents. The transition of the results obtained in therapeutic trials into daily clinical practice is often delayed or even hampered by monetary restrictions or reluctance of the medical community to adjust their approach to new treatments. After an initial inquiry had shown that less than 50% of eligible patients received any active immunomodulating treatment, a consensus group of Austrian, German and Swiss MS societies was formed in order to prepare a report of the current treatment options in MS. The aim of this report is to present the consensus on a new concept of escalating immunotherapy in MS. Future updates of the report are planned on a yearly basis or whenever substantial new evidence becomes available.
Introduction
With the introduction of new immunomodulating agents for the treatment of multiple sclerosis (MS), the therapeutic options for patients suffering from this potentially disabling disease have been improved. Although there is now clear evidence from large clinical trials that immunomodulatory treatment is effective in a significant proportion of patients with relapsing-remitting and to some extent also in secondary progressive MS, the transition of this knowledge into clinical practice is slow. For the German-speaking countries, it is estimated that only 15-20% of eligible patients actually receive immunomodulatory treatment with the new agents. Although the concept of stage-adapted treatment strategies arose [1, 2] , no consensus for standards of immunomodulatory treatment in MS is available. This situation in MS contrasts with that in medical oncology, where numerous consensus treatment protocols exist [3, 4] . As these new treatment compounds should be used prophylactically, the obvious question for an individual patient is how likely a relapse or progression of disability can be prevented. Important issues in making decisions for prophylactic treatment are the following [5] :
(1) Could you easily treat a relapse or disease progression you are trying to prevent if it happens?
(2) Is the prophylactic treatment effective? (3) If it works, how well does it work in general and compared with placebo, no treatment or other interventions that are currently in use? (4) Does the prophylactic agent have adverse effects? (5) Will the therapeutic treatment be safe and effective for my patients?
With regard to these questions, it is of paramount importance to determine how representative the study populations were with regard to disease duration, disability status and disease activity in comparison to patients seen in clinical practice. All modern MS treatment studies include study populations with restricted heterogeneity and use exclusion criteria and stratifications in order to yield representative and statistically significant results on treatment efficacy. Moreover, combination treatments are largely excluded from protocols before approval of either component.
The heterogeneity of MS and the number of available treatments preclude definitive studies with a reasonable group size to investigate the role of combination treatments, both simultaneous and sequential, in a stageadapted design.
The members of the medical advisory boards of the three neighboring MS societies expressed the necessity to form a consensus group that would critically review the evidence of available studies and consequently would develop guidelines both for practitioners and for health care providers. We therefore performed a systematic review of the available evidence from clinical trials with compounds currently available for the immunomodulatory treatment of MS. In principle, this report resembles those established by the Cochrane program (evidencebased medicine), but extends its perspective to more practical issues that are inherently empirical.
Methods
This consensus report is based on studies published in the medical scientific literature on immunomodulatory or immunosuppressive treatment of MS as well as case-control studies and well-documented case reports. According to the Quality Standards Subcommittee of the American Academy of Neurology [1] , the evidence was divided into three categories: class 1: evidence provided by one or more well-designed randomized control clinical trials; class 2: evidence provided by one or more well-designed clinical studies, such as controlled studies, cohort studies etc.; class 3: evidence provided by expert opinion, nonrandomized historical controls, or one or more case reports.
In addition to these three classes, the consensus group used further criteria for the evaluation of clinical studies, such as the availability of results from MRI studies, preservation of blinding of physician and patient to treatment, separation of the physician evaluating the patient by the expanded disability status scale (EDSS) from the treating physician, the availability of more than one study with identical or related compounds yielding similar therapeutic effects, and the consistency of the study results within a study.
A Medline search was conducted to identify articles on therapeutic trials with immunomodulatory agents in MS patients. These publications were evaluated by members of the Clinical Research Unit for MS and Neuroimmunology of the Julius Maximilians University of Würzburg and grouped according to the classification of evidence. The initial draft of the manuscript was discussed by the members of the consensus working group at the ECTRIMS meeting in Stockholm on September 12th 1998, and several consecutive versions were circulated among all members to reach consensus. The complete consensus statement was published in German in Der Nervenarzt [6] .
Results
An initial consensus was reached for the recommendation of immunomodulatory treatment in patients with MS. There was agreement that prophylactic treatment in patients with relapsing-remitting disease should be started early if the following criteria are fulfilled:
(1) Clinical definite diagnosis of MS of the relapsingremitting type according to the Poser criteria as well as intrathecal immunoglobulin G (IgG) synthesis or detection of oligoclonal bands and/or typical results of cranial MRI.
(2) Active disease with at least two functional relevant relapses during the 2 years or the occurrence of one severe exacerbation with delayed remission.
(3) Ability to walk at least 10 m with a cane (EDSS 6.5).
(4) Consent to perform effective contraception. As there are no final reports available on the application of immunomodulatory treatment in patients with signs of a single demyelinating lesion, we currently do not recommend the use of prophylactic treatment for this condition. However, several observations now support early prophylactic treatment in patients with a first clinical episode and paraclinical evidence of dissemination:
(1) Significant correlations can be found between the number of T 2 -weighted lesions on the initial cranial MRI and the extent of disability measured by Kurtzke's EDSS 10 years after the first clinical symptom [7] .
(2) A high relapse rate during the first 2 years after diagnosis is associated with poor prognosis [8] .
(3) Quantitative histopathological examinations revealed that axonal loss is present in active inflammatory lesions already early during the disease [9] .
Cessation of Immunomodulatory Therapy due to Treatment Failure
There is a need for a standardized definition of treatment failure in MS. The Quality Standard Subcommittee of the American Academy of Neurology has proposed a steady progression of disability for 6 months as a criterion to stop treatment with Betaseron ® [1] . In the available phase III studies, a confirmed progression of one point on the EDSS scale (or 0.5 points if EDSS scores are between 6 and 7) is usually regarded as an indication of treatment failure. In patients with relapsing-remitting disease, we consider an unaltered or increasing relapse rate, as well as the transition to a secondary progressive phase of the disease during an interval of 1 year as a robust measurement of treatment failure. There are currently no satisfying paraclinical criteria available to be substituted for a clinical definition.
For practical reasons, a distinction between primary and secondary treatment failure should be made. The former describes a patient whose disease course is not at all influenced by the immunoprophylactic treatment, whereas the latter indicates initial stabilization of the disease with later recurrence of relapse activity or clear-cut EDSS progression.
Options for Treatment Modifications
In general, the consensus group recommended that any modification of immunomodulatory therapy should be introduced exclusively in collaboration with an MS center. Due to the prophylactic character of the treatment, a reliable assessment of treatment efficacy should be made within 6-12 months after the initiation of therapy. In principle, there are several alternatives for treatment modifications, which should be evaluated in future clinical trials: (1) dose escalation, (2) modification of application intervals, (3) using a different compound and (4) augmentation of immunotherapy by the addition of one of several substances with additive or complementary modes of action.
Specific Treatment Modalities

Corticosteroid Treatment of Acute Relapses
There is convincing evidence that the application of high-dose steroids (500-1,000 mg methylprednisolone) is superior to only low-dose oral treatment. High-dose corticosteroid pulse therapy is indicated in patients with acute functional impairment, in order to reduce the symptoms of a relapse and to shorten the duration of an acute exacerbation. Except for the treatment of optic neuritis, oral tapering is not based on evidence from the studies reported so far. Overall, the group reached a consensus that high-dose steroid treatment should be offered to a patient if symptoms are disabling or markedly interfere with daily functions and well-being. There is only class 3 evidence available for which specific glucocorticosteroid should be used and for how long it can be applied if remission of severe symptoms is delayed. In patients with chronic progressive disease, intermittent steroid pulses may be considered. An ongoing immunomodulatory treatment should not be stopped during a steroid course intended to treat an acute relapse.
Interferon-ß
The efficacy of recombinant human interferon-beta (IFN-ß) preparations for the treatment of relapsing-remitting MS has been established in three large randomized, double-blind, placebo-controlled, multicenter, class 1 studies which were all successful in reaching their primary endpoints [11] [12] [13] . Although these studies cannot be directly compared (mainly due to different dosages, routes of administration, selection of primary endpoints and patient populations included in the study), they all demonstrated a significant effect on the reduction of relapse rates and can therefore be used in this indication. IFN-ß preparations (Betaferon ® 8 MIU subcutaneously every other day, Avonex ® 6 MIU intramuscularly once weekly and Rebif ® 6 MIU three times weekly subcutaneously) serve as basic immunomodulatory treatment options for patients with relapsing-remitting MS.
In choosing an IFN-ß for an individual patient, the consensus group recommended to consider the populations included in the different studies. In the Avonex study, a homogeneous group of patients with minor disability (EDSS 1-3.5) was recruited, whereas the Betaferon and PRISMS study included patients with higher grades of disability as well. In practical terms, it is of paramount importance to realistically inform patients about the potential of these new drugs, which are used to prevent future disease activity, but are not primarily focussed on the treatment of existing symptoms. Side effects of IFN-ßs as well as the differences in application frequency and route of administration should be explained to the patient to ensure proper compliance. Laboratory controls of hematological parameters and liver function should be performed during the first months of treatment. Neutralizing antibodies are not considered as useful markers of treatment failure [14] .
In patients who experience sustained and intolerable side effects with subcutaneous injections, but otherwise respond to treatment, a transition to the intramuscular application of IFN-ß1a (Avonex) may be considered. If there are persistent flu-like symptoms despite concomitant use of nonsteroidal anti-inflammatory drugs, a change from one IFN-ß to another is not likely to be of benefit for the patient.
As there are early reports on a dose-dependent increase in efficacy for IFN-ß1a (Rebif) with respect to the reduction of MRI activity and relapse rate [13, 15] , dose escalation for patients with treatment failure (as defined earlier) may be considered.
Treatment of Secondary Progressive MS
The large European study using Betaferon in patients with secondary progressive MS has been successful in delaying disease progression and reducing relapse frequency in all patient subgroups included [16] . Therefore, Betaferon (8 MIU every other day subcutaneously) may now be considered as the basic immunomodulatory therapy for patients with active secondary progressive disease.
Based on a prospectively planned interim analysis, the study was already stopped after 2 years instead of 3 years. More than 80% of patients had completed the whole study period and were available for the interim analysis, which supported the robust findings in this population of secondary progressive MS patients with over 50% of patients still showing considerable relapse activity.
Results of another IFN-ß trial (IFNß-1a, Rebif) in secondary progressive MS were recently presented at the 9th Conference of the European Neurological Society in Milano [17] . This trial failed to reach the primary endpoint (time to confirmed disease progression) mainly due to an unexpectedly slow progression rate of the male placebo group but demonstrated positive effects on relapse rate and new active lesions on cranial MRI.
Glatirameracetate (Copaxone ® )
Glatirameracetate (GLAT), a randomized synthetic oligopeptide, also known as copolymer-1, was initially used in experimental studies and demonstrated efficacy in ameliorating EAE. The first small clinical study with Copaxone in 50 patients with a very high relapse rate revealed a more than 70% reduction of exacerbations in the treated group [18] . The definite clinical trial demonstrated a 29% reduction of relapses after 2 years of treatment and significantly decreased the proportion of patients with unconfirmed disease progression [19] . In support of the main endpoints, these effects were sustained during the extension phase of the study [20] . A large double-blind, placebo-controlled trial on the effects of GLAT on cranial MRI in 239 patients has just been completed, and the results indicated a significant reduction of active MRI lesions during a 9-month period of treatment with glatirameracetate [21] .
The results of the Copaxone study regarding disease progression are difficult to compare with those from the IFN-ß trials, since different endpoint criteria were used. The consensus group regards GLAT as an alternative immunomodulatory treatment for relapsing-remitting patients without major functional disabilities who are not eligible for IFN-ß or have problems with side effects.
Intravenous Polyvalent Immunoglobulins of the IgG Class
The therapeutic efficacy of intravenous immunoglobulin (IVIg) has been established for a variety of immunemediated diseases of the peripheral nervous system [22] . After initial case reports about the use of IVIg in MS, class 1 evidence was provided by the Austrian Immunoglobulin in MS trial [23] . With a low dosage of 0.15-0.2 g/kg body weight intravenously per month, a significant reduction of the relapse rate and a higher proportion of patients with stable disease was reported. The study was only single-blinded, with the treating physician being aware of the study medication. Furthermore, disease progression was not confirmed, and therefore, the data should be interpreted with caution. Recent smaller studies using different IVIg preparations, higher dosages and closer application intervals [24, 25] revealed similar results, but with significant side effects at high concentrations [25] . At this point, the consensus group does not recommend IVIg as a first-line immunomodulatory treatment for relapsing-remitting MS ( fig. 1 ). There is agreement that several important questions, including optimal dose and application intervals as well as standardized preparation of this natural product need to be answered.
At the moment, the consensus group sees no compelling evidence that IVIg improves or induces remyelination in humans, which was suggested in only one small class 3 study in patients with optic neuritis [26] .
Azathioprine
Azathioprine is an immunosuppressive purine analogue with a long tradition in MS therapy. There is only one class 1 evidence study in patients with relapsing-remitting MS available [10] , but there are altogether five randomized, controlled studies in patients with different forms of MS [27, for review]. The designs of most studies using azathioprine do not fulfill criteria to accept them as class 1 studies in MS. The consensus group did not draw final conclusions as to the efficacy of azathioprine as an immunoprophylactic agent in MS. Future prospective studies should investigate azathioprine in comparison or in addition to IFN-ß and should include MRI as an outcome measure.
With these restrictions in mind, the consensus group regards azathioprine at a dose of 2-3 mg/kg body weight/ day as an alternative basic prophylactic treatment for those patients with relapsing-remitting MS who do not tolerate or accept parenterally applied therapies. Patients who have used azathioprine successfully for several years should remain on this regimen, as long as treatment does not exceed 10 years [28] . Regular control of blood cell counts and liver function tests is advised.
Mitoxantrone (Novantrone ® )
Mitoxantrone is a cytostatic anthracendione which is widely used for the treatment of malignant neoplasias. Its immunosuppressive effect in animal studies includes a strong antiproliferative action on B lymphocytes [29] . Mitoxantrone has a long biological half-life of 6 days. Overall, there are three class 1 evidence studies in patients with very active relapsing-remitting MS with favorable outcome including a large European multicenter trial presented recently at the ECTRIMS meeting in Stockholm [30] [31] [32] . The drug is very effective in reducing relapse rate and MRI activity and was shown to slow progression, even in patients with secondary progressive MS [32] . Due to its potentially severe side effects (e.g. congestive cardiomyopathy), related to total cumulative dose, mitoxantrone should presently only be used in selected patients with a very high relapse rate and incomplete remission or in those who do not respond to IFN-ß treatment. Although there is no class 1 evidence for the maximum safe dose of mitoxantrone, the consensus group recommends to use this drug for only up to 36 months at a concentration of 5-12 mg/m 2 body surface area and application intervals of 3 months. Monitoring of the quantitative ejection fraction by echocardiography, regular blood cell counts to detect the leukocyte nadir and tests for liver and kidney functions are advised. The drug should be discontinued if the left ventricular ejection fraction is reduced by more than 10% [33] .
Cyclophosphamide
There is no class 1 study available on the use of cyclophosphamide in MS patients. The results of the reported class 2 studies in patients with chronic progressive MS are conflicting [34, 35] . Subgroup analysis of one study [35] suggested that patients under the age of 40 with secondary progressive MS may benefit from monthly intravenous pulse therapies of cyclophosphamide (600 mg/m 2 body surface area) in conjunction with intravenous corticosteroids. The consensus group considers cyclophosphamide as a treatment option only in patients who do not respond to other therapies. Cyclophosphamide treatment should be introduced exclusively by an experienced MS center [36] .
Other Immunoprophylactic Treatments
The available evidence from limited clinical trials on other immunoprophylactic drugs, i.e. cladribin, cyclosporin A, linomide, sulfasalazin, 15-desoxyspergualin, oral myelin, plasmapheresis, stem cell transplantation, proteases or phosphodiesterase inhibitors, is not sufficiently conclusive to justify its use except in clinical trials. Some trials were already stopped due to severe toxicity of the drug (linomide).
Empirical Recommendations (Class 3 Evidence) for an Escalating Immunotherapy of MS
Natural history data from MS patients indicate that 2/3 of all patients with relapsing-remitting MS will finally enter a secondary progressive phase with accumulating functional deficits and disability. At the moment, there are no clear individual indicators or predictors for this transition of the disease process. Treatments therefore aim at reducing disease activity and delaying disease progression. From the available clinical trials, it can be concluded that effective prophylactic treatment options are available. This evidence was, however, obtained in highly selected patients and may not reflect the situation under usual clinical circumstances. Numerous patients in clinical practice have received some kind of immunomodulatory treatment and seek advice for optimization (patients with ongoing or recent disease-modifying drugs were not included in clinical trials).
Therapeutic concepts for patients who failed to respond to one or the other immunomodulating agent and their validation in defined clinical study protocols are warranted. In order to improve the currently available immunomodulatory treatment for MS patients, at the moment only 'best guess' expert opinions (class 3 evidence) for an escalating immunotherapy are expressed by the consensus group:
(1) Immunoprophylactic treatment, preferentially with one of the IFN-ßs, should be started early after a definite diagnosis of active MS has been established.
(2) In individual patients, depending on the individual situation (disease activity, compliance of the patient) other agents like Copaxone or azathioprine may be used as initial immunoprophylactic therapy.
(3) If intolerable local side effects prevent further application of subcutaneous IFN-ß (Betaferon, Rebif), treatment may be shifted to Avonex or one of the agents listed under (2) .
(4) In the case of treatment failure during IFN-ß medication, a higher dosage as well as changing to another immunosuppressive therapy ( fig. 1 ) may be considered.
The concept of escalating immunotherapy of MS, like in vasculitis or inflammatory connective tissue diseases [37] , would also imply that in patients with clinical stability of the disease for at least 6 months, de-escalation to basic immunomodulatory treatment should be considered. No studies are available to address this point. At the moment, any change in immunotherapy should be performed in cooperation with an experienced MS treatment center.
The consensus group agrees that this phase-adapted concept of immunotherapy and a rational combination of drugs eventually needs to be evaluated in clinical trials.
It is even conceivable that intensive immunotherapy of MS might even stop disease progression, as it has been shown in some patients with myasthenia gravis [38] or in lupus nephritis [39] .
